Loading
NASDAQHealthcareMedical - Devices
Latest quote
$60.61
−$3.24 · -5.07%
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.
Previous close
$60.61
−$3.24 · -5.07%
Regular session · ET · Market data may be delayed.
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.
Day range
Current $60.61
52-week range
Current $60.61
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
64
Undervalued
Sentiment
45
Mixed
Risk
36
Moderate Risk
Momentum
59
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.
Day range
Current $60.61
52-week range
Current $60.61
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 211.08M USD | 166.03M USD | 165.15M USD | 161.7M USD | 126.68M USD |
| Cost of goods sold | 64.77M USD | 56.5M USD | 58.17M USD | 55.11M USD | 41.28M USD |
| Gross profit | 146.31M USD | 109.53M USD | 106.98M USD | 106.6M USD | 85.4M USD |
| Research and development | 20.25M USD | 19.71M USD | 26.43M USD | 20.27M USD | 18.32M USD |
| Selling, general, and administrative | 165.07M USD | 139.81M USD | 145.58M USD | 125.98M USD | 92.23M USD |
| Operating expenses | 185.32M USD | 159.51M USD | 172M USD | 146.25M USD | 110.54M USD |
| Interest income | 423K USD | 1.48M USD | 1.02M USD | 87K USD | 23K USD |
| Interest expense | 25.26M USD | 20.83M USD | 15.39M USD | 11.76M USD | 9.06M USD |
| Depreciation and amortization | 10.47M USD | 7.58M USD | 4.88M USD | 4.34M USD | 4.12M USD |
| Operating income | −39.01M USD | −49.99M USD | −65.03M USD | −39.66M USD | −25.14M USD |
| Net income | −51.06M USD | −84.6M USD | −78.5M USD | −75.21M USD | −41.14M USD |
Company facts updated Oct 9, 2026.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM45.41M0.06%77.7B USD0.19%$277.57-0.05%
iShares Russell 2000 Growth ETFIWO16.16M0.12%14.04B USD0.24%$353.47-0.53%
Vanguard Russell 2000 ETFVTWO10.8M0.06%18B USD0.06%$112.1-0.10%
T. Rowe Price Small-Mid Cap ETFTMSL5.64M0.18%3.05B USD0.55%$40.940.00%
Vanguard Health Care ETFVHT3.92M0.02%22B USD0.09%$313.85-0.46%
First Trust Small Cap Growth AlphaDEX FundFYC3.4M0.25%1.77B USD0.70%$113.82-0.39%
Simplify Health Care ETFPINK3.36M1.08%317.6M USD0.51%$37.55-0.61%
Vanguard Russell 2000 Growth ETFVTWG2.05M0.12%1.7B USD0.06%$258.14-0.44%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOT. Rowe Price Small-Mid Cap ETFTMSLVanguard Health Care ETFVHTFirst Trust Small Cap Growth AlphaDEX FundFYCSimplify Health Care ETFPINKVanguard Russell 2000 Growth ETFVTWGAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
